Nonalcoholic Steatohepatitis

Annual Review of Medicine

Volumn 68, Issue , 2017, Pages 85-98

  Suzuki, Ayako ^a   Diehl, Anna Mae ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adaptive mechanisms; Hepatic fibrosis; Hepatocyte damage; Lipotoxicity; Nonalcoholic fatty liver disease

Indexed keywords

CELL DEATH; HUMAN; INFLAMMATION; LIPID STORAGE; LIPOTOXICITY; LIVER CELL; LIVER FIBROSIS; LIVER FUNCTION; LIVER INJURY; METABOLIC STRESS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEATOSIS; TISSUE REPAIR; COMPLICATION; HEPATITIS; LIPID METABOLISM; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

CELL DEATH; HEPATITIS; HEPATOCYTES; HUMANS; LIPID METABOLISM; LIVER; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85009961329     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-051215-031109     Document Type: Review

References (100)

1. Angulo P. 2002. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346:1221-31
2. Welsh JA, Karpen S, Vos MB. 2013. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J. Pediatrics 162:496-500e1
3. Kojima S, Watanabe N, Numata M, et al. 2003. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J. Gastroenterol. 38:954-61
4. Szczepaniak LS, Nurenberg P, Leonard D, et al. 2005. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am. J. Physiol. Endocrinol. Metab. 288:E462-68
5. Williams CD, Stengel J, Asike MI, et al. 2011. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140:124-31
6. Hui AY, Wong VW, Chan HL, et al. 2005. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment. Pharmacol. Ther. 21:407-13
7. Harrison SA, Torgerson S, Hayashi PH. 2003. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am. J. Gastroenterol. 98:2042-47
8. Angulo P, Kleiner DE, Dam-Larsen S, et al. 2015. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149:389-97e10
9. Rafiq N, Bai C, Fang Y, et al. 2009. Long-term follow-up of patients with nonalcoholic fatty liver. Clin. Gastroenterol. Hepatol. 7:234-38
10. Vernon G, Baranova A, Younossi ZM. 2011. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34:274-85
11. Jun DW, Han JH, Kim SH, et al. 2008. Association between low thigh fat and non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 23:888-93
12. Park SH, Kim BI, Kim SH, et al. 2007. Body fat distribution and insulin resistance: beyond obesity in nonalcoholic fatty liver disease among overweight men. J. Am. Coll. Nutr. 26:321-26
13. Richardson MM, Jonsson JR, Powell EE, et al. 2007. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 133:80-90
14. Hardy T, Oakley F, Anstee QM, et al. 2016. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum. Annu. Rev. Pathol. 11:451-96
15. Suzuki A, Abdelmalek MF. 2009. Nonalcoholic fatty liver disease in women. Womens Health 5:191-203
16. Suzuki A, Angulo P, Lymp J, et al. 2005. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 41:64-71
17. Nomura H, Kashiwagi S, Hayashi J, et al. 1988. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn. J. Med. 27:142-49
18. Clark JM, Brancati FL, Diehl AM. 2002. Nonalcoholic fatty liver disease. Gastroenterology 122:1649-57
19. Kagansky N, Levy S, Keter D, et al. 2004. Non-alcoholic fatty liver disease-a common and benign finding in octogenarian patients. Liver Int. 24:588-94
20. Suzuki A, Diehl AM. 2005. Should nonalcoholic fatty liver disease be treated differently in elderly patients Nat. Clin. Pract. Gastroenterol. Hepatol. 2:208-9
21. Chalasani N, Wilson L, Kleiner DE, et al. 2008. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J. Hepatol. 48:829-34
22. Yamaguchi K, Yang L, McCall S, et al. 2007. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45:1366-74
23. Leamy AK, Egnatchik RA, Shiota M, et al. 2014. Enhanced synthesis of saturated phospholipids is associated with ER stress and lipotoxicity in palmitate treated hepatic cells. J. Lipid Res. 55:1478-88
24. Sethi JK, Vidal-Puig AJ. 2007. Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J. Lipid Res. 48:1253-62
25. Cortes VA, Fernandez-GalileaM. 2015. Lipodystrophies: adipose tissue disorders with severe metabolic implications. J. Physiol. Biochem. 71:471-78
26. Margariti E, Deutsch M, Manolakopoulos S, et al. 2012. Non-alcoholic fatty liver disease may develop in individuals with normal body mass index. Ann. Gastroenterol. 25:45-51
27. Morita S, De-Santi Neto D, Morita FH, et al. 2015. Prevalence of non-alcoholic fatty liver disease and steatohepatitis risk factors in patients undergoing bariatric surgery. Obes. Surg. 25:2335-43
28. Alkhouri N, Dixon LJ, Feldstein AE. 2009. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev. Gastroenterol. Hepatol. 3:445-51
29. Hannah WN Jr., Harrison SA. 2016. Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease. Clin. Liver Dis. 20(2):339-50
30. Nielsen S, Guo Z, Johnson CM, et al. 2004. Splanchnic lipolysis in human obesity. J. Clin. Investig. 113:1582-88
31. Suzuki A, Abdelmalek MF, Unalp-Arida A, et al. 2010. Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 8:1062-69
32. Cheung O, Kapoor A, Puri P, et al. 2007. The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology 46:1091-100
33. Garaulet M, Perez-Llamas F, Baraza JC, et al. 2002. Body fat distribution in pre-and post-menopausal women: metabolic and anthropometric variables. J. Nutr. Health Aging 6:123-26
34. KvistH, Chowdhury B, Grangard U, et al. 1988. Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women: predictive equations. Am. J. Clin. Nutr. 48:1351-61
35. Klair JS, Yang JD, AbdelmalekMF, et al. 2016. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. Hepatology 64(1):85-91
36. Morse CG, McLaughlin M, Matthews L, et al. 2015. Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-monoinfected adults with elevated aminotransferase levels on antiretroviral therapy. Clin. Infect. Dis. 60:1569-78
37. Lee PL, Tang Y, Li H, et al. 2016. Raptor/mTORC1 loss in adipocytes causes progressive lipodystrophy and fatty liver disease. Mol. Metab. 5:422-32
38. JohnstonO, Rose CL, Webster AC, et al. 2008. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J. Am. Soc. Nephrol. 19:1411-18
39. Garg A. 2004. Acquired and inherited lipodystrophies. N. Engl. J. Med. 350:1220-34
40. Rinella ME, Green RM. 2004. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J. Hepatol. 40:47-51
41. Watanabe S, Horie Y, Suzuki A. 2005. Hepatocyte-specific Pten-deficient mice as a novel model for nonalcoholic steatohepatitis and hepatocellular carcinoma. Hepatol. Res. 33:161-66
42. Kudo Y, Tanaka Y, Tateishi K, et al. 2011. Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway. J. Hepatol. 55:1400-8
43. Hagenfeldt L, Wahren J, Pernow B, et al. 1972. Uptake of individual free fatty acids by skeletal muscle and liver in man. J. Clin. Investig. 51:2324-30
44. MachadoMV, Michelotti GA, Pereira de Almeida T, et al. 2015. Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis. Gut 64:1148-57
45. Liu J, Cinar R, XiongK, et al. 2013. Monounsaturated fatty acids generated via stearoylCoA desaturase-1 are endogenous inhibitors of fatty acid amide hydrolase. PNAS 110:18832-37
46. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. 2005. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Investig. 115:1298-305
47. Li ZZ, Berk M, McIntyre TM, et al. 2009. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J. Biol. Chem. 284:5637-44
48. Liu X, Burhans MS, Flowers MT, et al. 2016. Hepatic oleate regulates liver stress response partially through PGC-1alpha during high-carbohydrate feeding. J. Hepatol. 65:103-12
49. Vacca M, Allison M, Griffin JL, et al. 2015. Fatty acid and glucose sensors in hepatic lipid metabolism: implications in NAFLD. Semin. Liver Dis. 35:250-61
50. Noland RC, Koves TR, Seiler SE, et al. 2009. Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control. J. Biol. Chem. 284:22840-52
51. Kostapanos MS, Kei A, Elisaf MS. 2013. Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J. Hepatol. 5:470-78
52. Yoon M. 2010. PPARalpha in obesity: sex difference and estrogen involvement. PPAR Res. 2010:584296
53. Romano KA, Vivas EI, Amador-Noguez D, et al. 2015. Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-Noxide. mBio 6:e02481
54. McCarty MF, DiNicolantonio JJ. 2015. An increased need for dietary cysteine in support of glutathione synthesis may underlie the increased risk for mortality associated with low protein intake in the elderly. Age 37(5):96. doi: 10. 1007/s11357-015-9823-8
55. Fischer LM, daCosta KA, Kwock L, et al. 2007. Sex and menopausal status influence human dietary requirements for the nutrient choline. Am. J. Clin. Nutr. 85:1275-85
56. Ajuwon OR, Oguntibeju OO, Marnewick JL. 2014. Amelioration of lipopolysaccharide-induced liver injury by aqueous rooibos (Aspalathus linearis) extract via inhibition of pro-inflammatory cytokines and oxidative stress. BMC Complement. Altern. Med. 14:392. doi: 10. 1186/1472-6882-14-392
57. Brenner C, Galluzzi L, Kepp O, et al. 2013. Decoding cell death signals in liver inflammation. J. Hepatol. 59:583-94
58. Schneider JL, Cuervo AM. 2014. Liver autophagy: much more than just taking out the trash. Nat. Rev. Gastroenterol. Hepatol. 11:187-200
59. Boya P, Gonzalez-Polo RA, Casares N, et al. 2005. Inhibition of macroautophagy triggers apoptosis. Mol. Cell. Biol. 25:1025-40
60. Malhotra JD, Kaufman RJ. 2007. Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword Antioxidants Redox Signaling 9:2277-93
61. Hirsova P, Gores GJ. 2015. Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis. Cell. Mol. Gastroenterol. Hepatol. 1:17-27
62. Canbay A, Feldstein AE, Higuchi H, et al. 2003. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 38:1188-98
63. Caldwell S, Ikura Y, Dias D, et al. 2010. Hepatocellular ballooning in NASH. J. Hepatol. 53:719-23
64. Brunt EM, Tiniakos DG. 2010. Histopathology of nonalcoholic fatty liver disease. World J. Gastroenterol. 16:5286-96
65. Kakisaka K, Cazanave SC, Werneburg NW, et al. 2012. A hedgehog survival pathway in "undead" lipotoxic hepatocytes. J. Hepatol. 57:844-51
66. Bronner DN, O'Riordan MX, He Y. 2013. Caspase-2 mediates a Brucella abortus RB51-induced hybrid cell death having features of apoptosis and pyroptosis. Front. Cell Infect. Microbiol. Nov. 27(3):83. doi: 10. 3389/fcimb. 2013. 00083
67. Lebeaupin C, Proics E, de Bieville CH, et al. 2015. ER stress induces NLRP3 inflammasome activation and hepatocyte death. Cell Death Dis. 6:e1879
68. Sanman LE, Qian Y, Eisele NA, et al. 2016. Disruption of glycolytic flux is a signal for inflammasome signaling and pyroptotic cell death. eLife 24:5:e13663
69. Zanoni I, Tan Y, Di Gioia M, et al. 2016. An endogenous caspase-11 ligand elicits interleukin-1 release from living dendritic cells. Science 352:1232-36
70. Andersen CJ, Murphy KE, Fernandez ML. 2016. Impact of obesity and metabolic syndrome on immunity. Adv. Nutr. 7:66-75
71. Cavalcante-Silva LH, Galvao JG, da Silva JS, et al. 2015. Obesity-driven gut microbiota inflammatory pathways to metabolic syndrome. Front. Physiol. Nov. 19(6):341. doi: 10. 3389/fphys. 2015. 00341
72. Lackey DE, Olefsky JM. 2016. Regulation of metabolism by the innate immune system. Nat. Rev. Endocrinol. 12:15-28
73. Lynch L, Nowak M, Varghese B, et al. 2012. Adipose tissue invariant NKT cells protect against dietinduced obesity and metabolic disorder through regulatory cytokine production. Immunity 37:574-87
74. Chandra RK. 1980. Cell-mediated immunity in genetically obese (C57BL/6J ob/ob) mice. Am. J. Clin. Nutr. 33:13-16
75. Ley RE, Backhed F, Turnbaugh P, et al. 2005. Obesity alters gut microbial ecology. PNAS 102:11070-75
76. Guebre-Xabier M, Yang S, Lin HZ, et al. 2000. Altered hepatic lymphocyte subpopulations in obesityrelated murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology 31:633-40
77. Honda H, Ikejima K, Hirose M, et al. 2002. Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 36:12-21
78. Syn WK, Agboola KM, Swiderska M, et al. 2012. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut 61:1323-29
79. Kremer M, Hines IN. 2008. Natural killer T cells and non-alcoholic fatty liver disease: fat chews on the immune system. World J. Gastroenterol. 14:487-88
80. Syn WK, Oo YH, Pereira TA, et al. 2010. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 51:1998-2007
81. Friedman SL. 2008. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 88:125-72
82. KramannR, Schneider RK, DiRocco DP, et al. 2015. Perivascular Gli1+progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell 16:51-66
83. Michelotti GA, Xie G, Swiderska M, et al. 2013. Smoothened is a master regulator of adult liver repair. J. Clin. Investig. 123:2380-94
84. Omenetti A, Choi S, Michelotti G, et al. 2011. Hedgehog signaling in the liver. J. Hepatol. 54:366-73
85. Ochoa B, Syn WK, Delgado I, et al. 2010. Hedgehog signaling is critical for normal liver regeneration after partial hepatectomy in mice. Hepatology 51:1712-23
86. Syn WK, Jung Y, Omenetti A, et al. 2009. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 137:1478-88
87. Rangwala F, Guy CD, Lu J, et al. 2011. Increased production of sonic hedgehog by ballooned hepatocytes. J. Pathol. 224:401-10
88. Guy CD, Suzuki A, Zdanowicz M, et al. 2012. Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology 55:1711-21
89. Guy CD, Suzuki A, Abdelmalek MF, et al. 2015. Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity. Hepatology 61:98-107
90. Chung SI, Moon H, Ju HL, et al. 2016. Hepatic expression of SonicHedgehog induces liver fibrosis and promotes hepatocarcinogenesis in a transgenic mouse model. J. Hepatol. 64:618-27
91. Myers BR, Sever N, Chong YC, et al. 2013. Hedgehog pathway modulation by multiple lipid binding sites on the smoothened effector of signal response. Dev. Cell 26:346-57
92. Pospisilik JA, Schramek D, Schnidar H, et al. 2010. Drosophila genome-wide obesity screen reveals hedgehog as a determinant of brown versus white adipose cell fate. Cell 140:148-60
93. Teperino R, Amann S, BayerM, et al. 2012. Hedgehog partial agonism drives Warburg-likemetabolism in muscle and brown fat. Cell 151:414-26
94. Keramati AR, Fathzadeh M, Go GW, et al. 2014. A form of the metabolic syndrome associated with mutations in DYRK1B. N. Engl. J. Med. 370:1909-19
95. Lim GE, Albrecht T, Piske M, et al. 2015. 14-3-3 coordinates adipogenesis of visceral fat. Nat.commun. 6:7671
96. Borggrefe T, Lauth M, Zwijsen A, et al. 2016. The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGF/BMP and hypoxia pathways. Biochim. Biophys. Acta. 1863:303-13
97. Shi Y, Chen J, Karner CM, et al. 2015. Hedgehog signaling activates a positive feedback mechanism involving insulin-like growth factors to induce osteoblast differentiation. PNAS 112:4678-83
98. Varelas X. 2014. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development 141:1614-26
99. Wehner D, Weidinger G. 2015. Signaling networks organizing regenerative growth of the zebrafish fin. Trends Genet. 31:336-43
100. Jerde TJ. 2015. Phosphatase and tensin homologue: novel regulation by developmental signaling. J. Signal Transduct. 2015:282567. doi: 10. 1155/2015/282567